XTuit nets $22 mln in Series A round with help from CTI Life Sciences
U.S. biopharmaceutical company XTuit Pharmaceuticals Inc has received US$22 million in a Series A financing. The round was led by U.S. venture capital firm New Enterprise Associates and joined by founding investor Polaris Partners, as well as new investors, which included Canadian firm CTI Life Sciences. XTuit, which is developing a novel class of therapeutics targeting disease-promoting microenvironment in cancer and fibrotic diseases, said it will use the proceeds of the deal to advance development of its lead products and to build its biomarker platform. In January, CTI secured $134 million in the first close of its second fund, CTI II.
11 June 2015•5 mins read
